Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study

Foster, Stephan L.; Balkaran, Bridget L.; Cambron-Mellott, M. Janelle; Samaan, Karen; Mason, Oksana; Ye, Wenyu; Rowland, Jem J.; Jaffe, Dena H

doi:10.1080/03007995.2020.1865749

Cited by 1 publication

(1 citation statement)

References 45 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Komodo's 'payer-complete' population includes prescription and/or medical claims of >140 million patients collected from >150 private insurers in the USA, including Medicaid Managed Care and Medicare Advantage plans. Further details on the Komodo Health claims database have been reported in prior studies [21][22][23]. National Provider Identifier codes from the claims data were used to determine the characteristics of those providers who prescribed rituximab-pvvr (or rituximab reference medication in exploratory analysis) to the patients included in the sample.…”

Section: Study Design and Data Sourcementioning

confidence: 99%

Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA

et al. 2021

View full text Add to dashboard Cite

Aim: To describe treatment patterns and patient and provider characteristics associated with the recently introduced biosimilar rituximab-pvvr. Methods: This retrospective analysis included adult patients with one or more claims for rituximab-pvvr, with an index date of 23 January 2020 and a study period covering 1 January 2019–31 July 2020. Results: Of 249 patients included, the most common rituximab-pvvr indications were non-Hodgkin’s lymphoma (77.5%) and chronic lymphocytic leukemia (11.2%). Some patients with non-Hodgkin’s lymphoma (42.5%) and chronic lymphocytic leukemia (39.3%) switched to rituximab-pvvr from the reference product or another rituximab biosimilar. Most patients were aged ≥65 years (63.5%) and were male (54.6%). Most (59.0%) rituximab-pvvr prescribers practiced in the south of the USA. Conclusion: Utilization occurred in approved and extrapolated indications. These preliminary findings suggest switching between reference product and rituximab biosimilars; rituximab-pvvr combination regimens are being adopted in real-world oncology practice.

show abstract

Section: Study Design and Data Sourcementioning

confidence: 99%